Empagliflozin in ADPKD with suspected IgA nephropathy: antiproteinuric response without adverse events - PubMed
3 hours ago
- #SGLT2 inhibitors
- #proteinuria
- #ADPKD
- SGLT2 inhibitors are underused in ADPKD due to limited data and theoretical safety concerns.
- A 58-year-old male with PKD2-associated ADPKD had increasing proteinuria despite ACE inhibitor therapy.
- Clinical findings suggested IgA nephropathy, but biopsy was contraindicated.
- Empagliflozin 10 mg/day reduced proteinuria from 2.0 g/24 h to 0.3-0.4 g/24 h over 18 months (82-85% reduction).
- Renal function remained stable with no infections or adverse events.
- The case supports the safety and antiproteinuric efficacy of empagliflozin in ADPKD with superimposed glomerular disease.